Larissa Anthony, PA
Physician Assistant · Phoenix, AZNPI 1093099855
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,793 of the $31,909 with a category attached, or 65.2%. 51 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. Among physician assistant clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 930 payments — averaging $34.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Sanofi$6K
- Inspire Medical Systems, Inc.$2K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Boehringer Ingelheim$1K
- plus $10K from 45 others
Across 22 payments — averaging $172.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$4K
What the payments were for
- Consulting fees$5,03216%
- Speaking & faculty fees$3,10010%
- Travel & lodging$2,0376%
- Food & beverage$20,79365%
- Education$9473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,909 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 960 | $861,546 |
| Dupixent PenDupilumab | 81 | $360,569 |
| OfevNintedanib Esylate | 21 | $288,013 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 229 | $174,549 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $142,240 |
| Dupixent SyringeDupilumab | 27 | $104,837 |
| Breo ElliptaFluticasone/Vilanterol | 170 | $104,086 |
| TezspireTezepelumab-Ekko | 16 | $70,727 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 102 | $51,391 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 81 | $50,419 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 153 | $37,309 |
| SymbicortBudesonide/Formoterol Fumarate | 97 | $36,893 |
| Spiriva HandihalerTiotropium Bromide | 40 | $35,333 |
| Spiriva RespimatTiotropium Bromide | 49 | $34,862 |
| Advair HfaFluticasone Propion/Salmeterol | 66 | $32,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,006 | $1,065,1831,354 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,430 | $373,294151 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Airsupra, Bevespi Aerosphere | $9,009 | $307,839398 claims |
| Grifols USA, LLCProlastin C | $155 | $142,24012 claims |
| PfizerEliquis | $36 | $16,85425 claims |
| MerckDulera | $306 | $9,71018 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $31 | $6,58114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.
Other physician assistant in Phoenix
- Katherine MinorPhoenix$76K
- Micah LasleyPhoenix$52K
- Thomas SirrinePhoenix$37K
- Karla HortonPhoenix$36K
- Tana FrumentoPhoenix$25K
- Rosemary SrisukPhoenix$17K
- John DorseyPhoenix$17K
- Kendall SmithPhoenix$16K
- Theresa PinderPhoenix$16K
- Arturo SanchezPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.